QEEG indices in traumatic brain injury - insights from the CAPTAIN RTMS trial.

Olivia VR, Chira D, Chelaru VF, Diana CD, Livia LP, Buruiană AM, Mureşanu FD

Journal of medicine and life1 Mar 2024Cited by 5 (Europe PMC)

PMID39044922PMCIDPMC11262599DOI10.25122/jml-2024-0187PepBankPUB-39044922

Summary

This secondary analysis of the CAPTAIN-RTMS trial data focused on the significance of quantitative electroencephalography (qEEG) indices as indicators of recovery in patients with traumatic brain injury (TBI). By focusing on the delta alpha ratio (DAR), delta theta/alpha beta ratio (DTABR), and theta beta ratio (TBR), this study explored the shifts in brainwave activity as a response to an integrative treatment regimen of repetitive transcranial magnetic stimulation (rTMS) combined with the neurotrophic agent Cerebrolysin. Findings revealed significant increases in DAR and DTABR, suggesting changes in neurophysiological dynamics after treatment. However, variations in TBR were inconclusive in providing clear electrophysiological insights. These results indicate that further research is necessary to describe and understand the underlying mechanisms of brain recovery and to develop refined treatment frameworks for patients with TBI.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cerebrolysin.

01HumanNot a test of Cerebrolysin aloneOther designActivity measurement
In TBI patients, rTMS combined with Cerebrolysin significantly increased the delta alpha ratio after treatment.
In plain wordsIn patients with brain injury, rTMS combined with Cerebrolysin increased the delta alpha ratio after treatment.
Peptide
Cerebrolysin
Outcome
IncreaseDelta alpha ratio
Study
n: not reported in source
Outcome group
Brain and neuronal activity · Nervous system and cognition
Source sentences
Summary
Findings revealed significant increases in DAR and DTABR, suggesting changes in neurophysiological dynamics after treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
This secondary analysis of the CAPTAIN-RTMS trial data focused on the significance of quantitative electroencephalography (qEEG) indices as indicators of recovery in patients with traumatic brain injury (TBI).
Summary · context
By focusing on the delta alpha ratio (DAR), delta theta/alpha beta ratio (DTABR), and theta beta ratio (TBR), this study explored the shifts in brainwave activity as a response to an integrative treatment regimen of repetitive transcranial magnetic stimulation (rTMS) combined with the neurotrophic agent Cerebrolysin.
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Show in the study text Report a problemFND-3904492201
02HumanNot a test of Cerebrolysin aloneOther designActivity measurement
In TBI patients, rTMS combined with Cerebrolysin significantly increased the delta theta/alpha beta ratio after treatment.
In plain wordsIn patients with brain injury, rTMS combined with Cerebrolysin increased the delta theta/alpha beta ratio after treatment.
Peptide
Cerebrolysin
Outcome
IncreaseDelta theta/alpha beta ratio
Study
n: not reported in source
Outcome group
Brain and neuronal activity · Nervous system and cognition
Source sentences
Summary
Findings revealed significant increases in DAR and DTABR, suggesting changes in neurophysiological dynamics after treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
This secondary analysis of the CAPTAIN-RTMS trial data focused on the significance of quantitative electroencephalography (qEEG) indices as indicators of recovery in patients with traumatic brain injury (TBI).
Summary · context
By focusing on the delta alpha ratio (DAR), delta theta/alpha beta ratio (DTABR), and theta beta ratio (TBR), this study explored the shifts in brainwave activity as a response to an integrative treatment regimen of repetitive transcranial magnetic stimulation (rTMS) combined with the neurotrophic agent Cerebrolysin.
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Show in the study text Report a problemFND-3904492202
03HumanNot a test of Cerebrolysin aloneOther designActivity measurement
In TBI patients receiving rTMS combined with Cerebrolysin, theta beta ratio variations were inconclusive.
In plain wordsIn patients with brain injury receiving rTMS combined with Cerebrolysin, theta beta ratio changes were inconclusive.
Peptide
Cerebrolysin
Outcome
Direction not reportedTheta beta ratio
Study
n: not reported in source
Outcome group
Brain and neuronal activity · Nervous system and cognition
Source sentences
Summary
However, variations in TBR were inconclusive in providing clear electrophysiological insights.
2 context sentences(design, population, supporting numbers)
Summary · context
This secondary analysis of the CAPTAIN-RTMS trial data focused on the significance of quantitative electroencephalography (qEEG) indices as indicators of recovery in patients with traumatic brain injury (TBI).
Summary · context
By focusing on the delta alpha ratio (DAR), delta theta/alpha beta ratio (DTABR), and theta beta ratio (TBR), this study explored the shifts in brainwave activity as a response to an integrative treatment regimen of repetitive transcranial magnetic stimulation (rTMS) combined with the neurotrophic agent Cerebrolysin.
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Show in the study text Report a problemFND-3904492203

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.